Vaira Leimane

Summary

Country: Latvia

Publications

  1. ncbi request reprint Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study
    Vaira Leimane
    State Centre of Tuberculosis and Lung Diseases, Riga, Latvia
    Lancet 365:318-26. 2005
  2. pmc Multidrug-resistant tuberculosis detection, Latvia
    Girts Skenders
    State Centre of Tuberculosis and Lung Diseases, Riga, Latvia
    Emerg Infect Dis 11:1461-3. 2005
  3. pmc Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
    Vija Skripconoka
    Riga East University Hospital, Centre of Tuberculosis and Lung Diseases, Riga, Latvia
    Eur Respir J 41:1393-400. 2013
  4. ncbi request reprint Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome
    Timothy H Holtz
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Ann Intern Med 144:650-9. 2006
  5. pmc Multidrug-resistant tuberculosis management in resource-limited settings
    Eva Nathanson
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Emerg Infect Dis 12:1389-97. 2006

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study
    Vaira Leimane
    State Centre of Tuberculosis and Lung Diseases, Riga, Latvia
    Lancet 365:318-26. 2005
    ..Latvia has one of the highest rates of multidrug-resistant tuberculosis (MDRTB). Our aim was to assess treatment outcomes for the first full cohort of MDRTB patients treated under Latvia's DOTS-Plus strategy following WHO guidelines...
  2. pmc Multidrug-resistant tuberculosis detection, Latvia
    Girts Skenders
    State Centre of Tuberculosis and Lung Diseases, Riga, Latvia
    Emerg Infect Dis 11:1461-3. 2005
    ..The assay detected rifampin resistance with 91% sensitivity and 96% specificity within 1 to 5 days (vs. 12-47 days for BACTEC)...
  3. pmc Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
    Vija Skripconoka
    Riga East University Hospital, Centre of Tuberculosis and Lung Diseases, Riga, Latvia
    Eur Respir J 41:1393-400. 2013
    ....
  4. ncbi request reprint Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome
    Timothy H Holtz
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Ann Intern Med 144:650-9. 2006
    ....
  5. pmc Multidrug-resistant tuberculosis management in resource-limited settings
    Eva Nathanson
    Stop TB Department, World Health Organization, Geneva, Switzerland
    Emerg Infect Dis 12:1389-97. 2006
    ..In resource-limited settings, treatment of MDRTB provided through, or in collaboration with, national TB programs can yield results similar to those from wealthier settings...